affordable innovation - jubilant life sciences ltd · 2013-05-06 · molecular design...

AffordableInnovation

Innovate | Collaborate | Accelerate

www.jubilantbiosys.com www.jchemsys.com

Our Values

We will carefully select, train and develop our people to be creative, empower them to take decisions, so that they respond to all customers with agility, confidence and teamwork.

We stretch ourselves to be cost effective and efficient in all aspects of our operations and focus on flawless delivery to create and provide the best value to our customers.

By sharing our knowledge and learning from each other and from the markets we serve, we will continue to surprise our customers with innovative solutions.

With utmost care for the environment and safety, we will always strive to excel in the quality of our processes, our products and our services.

Our Promise

Caring, Sharing, Growing

We will, with utmost care for the environment

and society, Continue to enhance value for our

customers by providing innovative products and

economically efficient solutions; and for our

stakeholders through growth, cost effectiveness

and wise investment of resources

Our Vision & Our Values

Our Vision

To be the most admired

global life sciences

company enabling

biopharmaceutical

industry to improve

Human Health.

Jubilant Biosys Ltd & Jubilant Chemsys Ltd are part of the Jubilant LifeSciences providing innovative drug discovery solutions to the global pharmaceutical industry. Also called Jubilant Drug Discovery services (JDDS), is enabled through its locations across India and the USA.

Jubilant offers integrated discovery solutions spanning across Target Identification/Target Validation (TI/TV) to Lead Optimization (LO)/Preclinical candidate (PCC), for multiple therapeutic areas.

With well enabled capabilities in Oncology, Metabolic Disorders, CNS, Pain and Inflammation, Jubilant has rapidly emerged as a leading collaborator for biotechnology and pharmaceutical companies worldwide.

In each of these therapeutic areas, Jubilant has developed in-depth expertise in discovery informatics, medicinal chemistry, structural biology, biology, in-vivo and in-vitro biology and translational sciences.

The discovery team focuses on early stage lead generation across various target classes and uses a wide range of technologies, including high throughput screening, molecular modeling, medicinal chemistry, structural biology and others, to identify novel starting points that are then selectively taken through the preclinical discovery process. This is further augmented by our expertise in Animal Pharmacology with multiple pharmacology and in-vivo models enabled internally to deliver high quality IND ready candidates. Jubilant continues to demonstrate optimal to excellent outcomes to our global pharmaceutical collaborators.

Jubilant Drug Discovery:

• 700+ people working on drug discovery spread across three locations Noida and Bangalore in India and Malvern in the USA.

• Demonstrated outcomes and expertise: ~50 programs leading to preclinical decision outcomes with some leading to successful clinical outcomes across multiple therapeutic areas.

• Exploratory and translational outcomes across target and disease platforms enabling “right shots at the goal”.

• Integrated and robust preclinical and “early stage POC” portfolio management.

Jubilant operates on a customized approach offering innovative solutions across the Drug Discovery value chain to the Biotechnology and Pharmaceutical Industry. To suit each client’s requirements in the best possible manner, we offer flexibility through the following Business Models:

• Full Time Equivalent (FTE) based

• Fee For Service (FFS) based

• Integrated Drug Discovery Programs

• Milestone & Hybrid Models

• Risk Sharing Model

Jubilant collaborates with the world’s leading pharmaceutical and biotech companies, academic institutions and research foundations. Innovative and rigorous science, excellence in execution, and absolute integrity, combined with flexible business models has enabled Jubilant to deliver valuable outcomes in a relatively short period of time. The hallmark of Jubilant’s collaborative model is the creation of value to their partners.

Certified ISO 27001:2005 (By British Standards Institution, India)Ju

bila

nt D

rug

Dis

cove

ry S

ervi

ces

Integrated

Integrated Drug Discovery

• Seamless integration from target validation to candidate selection under one roof • Non-GLP tox capabilities • ~50 integrated

projects enabled • Delivered 3 clinical candidates in last 4 years and 3 more expected in IND enabling efforts • PD and Disease model

expertise • 8-10 validated models/TA • Virtual Pharmacology Lab - funcional service for Pain

Initiated Plans

o Tumors from Cancer patients (Kolkata Hospital)

o Target / substrate expression

o Cell culture

o Mutation analysis

o Xenograft model with primary human tumor

Expansion Plans

o PoM / Target Engagement Biochemical Biomarkers rodent / human accessible tissue

o Test leads in tumor cell lines for molecular profiling & biomarkers

Already In Place

o Dose to Man Predictions

Small Molecule Design• In silico predictions • Virtual libraries • Structure-based design • Ligand-bound structure generation • Rapid HTS follow up •

Rational Design from competitor molecules to generate novel IP

Target Classes• GPCRs • Kinases • Ion-channels • NHRs • Proteases • Epigenetics • Protein-Protein Interactions

Jubilant demonstrated expertise: Differentiated Enablers

Jubilant Drug Discovery Services (JDDS) Sites: Biosys-Bangalore; Chemsys-Noida; Malvern-PA.

Seamless Integration

Drug Discovery Capabilities

TI/TV: Bioinformatics, Target proposal (line-of-sight to IND), Target Validation (siRNA, tool cmpds, expression) Build: Target & pathway

expression in human disease tissue, patient stratification

Lead Optimization & Preclinical Devevlopment: Med / Synth Chem, DMPK, in vivo PD & disease models, scale-up, preformulation, non-

GLP Tox, D2M predictions.

Build: Human pharmacodynamic / target engagement biomarkers.

Hit to Lead: HTS, Structural Biology (protein, X-ray crystallography), Med / Comp Chem, in vitro ADME, in vitro / Cell biology Build: Frag-

ment & Lead Library synthesis, human cells (primary)

Target Identification &Validation

Hit to Lead Generation

Lead Optimization &Preclinical Development

[email protected] | www.jubilantbiosys.com [email protected] | www.jchemsys.com

• Core of innovation, data management and building customer

confidentiality

• >300 Chemists with +10 years of expertise dedicated

overpowering synthetic challenges of delivery compounds

• Individually tailoring the needs of clients facilitated FTEs to be

delivered ranging from milligrams to kilograms

• Access Controlled Modular Laboratories

• Milestone-based contracts enable you to pay for performance

and not just activity

• Armored with an upfront work plan sanctions the efficacy of

protocol preparation

• Standard terms and Conditions simplify and encourage lasting

relationships

Molecular Modeling

Design capabilityTools, Proprietary Tech

Docking studies

Synthetic Organic Chemistry Medicinal Chemistry

SAR/Lead optimization

HTL,LO,PCC

Process Research & Optimization

Design, Development, Process execution

Scale-up, Material supply for pre-clinical/tox studies

Analytical Characterization

Methoddevelopment

Purification

Synthesis of scaffolds, building blocks,intermediates, reference compounds

Library Design and synthesis

Noida Site

• Expanded Synthetic chemistry

• Scale up facility - Tox • Pre-formulation and

formulation development

• Special Expertise • Carbohydrate Chemistry • Nucleoside Chemistry • Focused Libraries

• Expertise • Drug design • SAR Optimization • Pharmaceutical properties

optimization

• Therapeutic Areas • Oncology • CNS • Metabolic Disorders • Pain and Inflammation

Bangalore Site

Jubilant Chemistry Competence

Discovery EnablersChemistry Services

Quality and Deliverables Intellectual Property Data Storage & IP

• Guarantee the standards most suitable to your needs

• To achieve and accommodate a high standard of protection by upgraded access control panels

Service Highlights

• Ensuring that the consumer rights are inevitable served


Target Classes• Kinases• GPCRs• NHRs• Ion Channels• Proteases• Transporters• Enzymes

Compound Management System• HTS REMP Sample Management Store

Base and Extension

Assay Technologies• Radiometric SPA/filter binding• Fluorescence/colorimetric • HTRF• Alphascreen • ELISA • Atomic absorption• Patch clamp• FACS

Animal Facilities• Nude mice• Rodents

In vivo Efficacy Models (PK-PD)• Oncology• Diabetes/Obesity• CNS• Pain and Inflammation • Respiratory

Biology Assay Development & Validation• Biochemical assays• Cell Based Assays• Target or Pathway Specific Assays• Phenotypic Assays

Drug Discovery (Target to IND)

Target ID & Validation Lead Op & PCCTarget to Hit Hit to Lead IND

• Biobanking• Tissue Banking• Patient sample analysis• Literature mining• Bioinformatics• siRNA• Tool compounds• Cell and animal models

• Gene cloning• Protein Expression and

Purification• Apo and Ligand bound

structures• Biochemical & Cell based

assay development• Screening• In vitro ADME

• Cell based mechanistic and functional assays

• PK, PK-PD• Efficacy Biomarkers• CYP Inhibition• hERG liability Acute

Tox

• PK-PD• Efficacy in multiple

models• Biomarkers• Multiple species PK• Off-target profiling• Gene Tox• TK, Acute and Chronic

Tox

• Preformulation• Regulatory Tox• IND filing

Enabling Discovery across the value chain

Discovery EnablersBiology

Value Addition

Bio-banking-Biomarker Research

Target Identification and Validation

Enhanced Capabilities

HT - Electrophysiology

High Throughput Screening

Ion Channels; GPCRs; Kinases

hERG e-phys

off - Target Screens

Med.Chem

ADME/PKIn vivo

Tox

HTS e-phys

Assays


Human Tissue Banking• Alliance with local hospital and institutions • Access to human disease tissue • Translational research capabilities

Discovery EnablersDMPK & Toxicology

Jubilant discovery DMPK offers a broad range of high quality services in the areas of in vitro ADME, in vivo PK/TK and bioanalysis, either as part of integrated programs or as a standalone. With investment in state-of-the-art mass spectrometry (LC-MS/MS, HPLC-UV/PDA), automated high throughput sample preparation, robotics and world class laboratory data management Galileo™ and Watson™ LIMS systems, we are capable to work in medium to high throughput environment. Our animal facilities have been accredited by CPCSEA and support a broad range of in vivo DMPK studies involving rat, mice, genetically modified mice and rabbits. We have collaborated with external partners for conducting the dog and monkey PK life phase and bioanalysis is being done at our Bangalore research centre.

Jubilant has a highly skilled and competent scientific team committed to deliver quality results with quick turnaround time. We work closely with our clients, understand their requirement and are flexible in modifying the assay protocols, report templates to match client’s expectation.

The Animal Facility is registered with “Committee for the Purpose of Control and Supervision of Experiments on Animals” (CPCSEA) and AAALAC accredited.

Discovery Enablers-DMPK & Toxicology

Target to Hit

Assessment of physicochemical & In

vitro ADME properties

• In silico properties• Solubility• Log D• Microsomal stability• CYP inhibition

• Solubility• Log D• Metabolic stability• CYP inhibition• Permeability• Plasma protein binding• In vivo PK (rodent)• Reactive metabolite

Optimization of physicochemical &

druggableproperties

Hit to Lead

• Dose range finding (rodent and non- rodent)

• PK/PD• Tissue distribution• Food effect• Metabolite profiling• Safety profiling• Toxicokinetics• CYP induction• Interspecies scaling

Dose range finding, Safety/Tox assessment,

Interspecies scaling

Candidate selection

• Metabolic stability• DDI, TDI/MBI• Permeability (Caco-2,

MDCK-MDR1)• Plasma protein binding• In vivo PK (rodent)• In vivo PK (non-rodent) • Target tissue exposure• Blood/plasma partioning • IVIVC, Renal/Biliary CL• Mass balance• PK/PD• Met id (soft spot)• Dose-to-man prediction

Optimization of druggable properties,

IVIVC, PK/PD correlation

Lead to optimized lead/ candidate

identification

DMPK Support Across Discovery Chain

Services

• Bioanalytical method

development and validation

• Metabolite identification

• PK and TK in rodent/non-rodents

• Mass balance studies

• Chiral chromatography

• Cocktail analysis

• Formulation analysis

• Plasma protein binding

• Metabolic stability

• Solubility, LogD

• In vitro DDI studies

• Permeability studies

• Preclinical formulation development

TOXICOLOGY & GENOTOX (Non-GLP)Genotoxicity:• Ames test • Chromosomal Aberration test • Micronucleus test

Toxicology:• Acute toxicity studies in Rats and mice• MTD studies in rat and mice with TK• Dose escalation and range-finding• 4, 7 and 14 day studies in rat and mice with TK


Jubilant Biosys computational chemistry team excels in drug discovery design efforts in collaboration with medicinal chemistry, structural biology biology and DMPK teams, by conducting molecular modeling studies - pharmacophore and QSAR modeling, protein structure-based drug design, ligand-based drug design, fragment-based drug design, homology modeling, docking & scoring, chemoinformatics analysis and de novo design. The team of 20 scientists extensively utilizes in-house expertise in software development, chemo-curation and structural biology for driving molecular design.

Achievements

• The Jubilant modeling group is actively involved in over twenty integrated drug discovery projects and modeling collaborations.• Molecular modeling and structure-based drug design techniques have been employed in the development of two clinical candidates

(GPCR, kinase targets) and a back up candidate (protease target) for clinical trials.• Jubilant computational chemistry group played a critical role in the design and successful development of multi-kinase inhibitor series for

multiple projects:• Two different, novel and potent lead series of inhibitors for a dual kinase inhibitor program• Two different lead series of novel, potent inhibitors for a triple kinase inhibitor program

Molecular Design Collaborations (MDC)• Jubilant computational chemistry team empowers drug discovery scientists to deploy ready-to-use models and make faster and wiser

decisions:

• Virtual screening• Protein-ligand

interactions• Validated docking

models and scoring• SAR analysis• Selectivity analysis• Activity prediction• Suggestions for synthesis

/ testing

• Template search• Validated homology

models• Sequence analysis• Structural analysis• Comparison of

homologous proteins

• Validated pharmacophore/ 3D-/2D-QSAR models

• Activity prediction• SAR analysis• Selectivity analysis• Cluster analysis• Suggestions for synthesis

/ testing

• Analysis of PDBs• Compare & characterize

binding sites• PDB water analysis• Calculate ligand

properties• Correlate activity &

properties

Docking Homology modeling MiscellaneousPharmacophore/ QSAR

IC50 = x IC50 > x/1000Apo enzyme

Fragment based drug discovery

Discovery EnablersComputational Chemistry

ReportsStructural Biology

Chemistry

Models

Structural Biology

Data

Biology

Chemo Informatics

Bio Informatics Pharmacology

Computational & Informatics

Support


Jubilant has the most experienced Structural Biology team,

offering integrated and functional services

Integrated Drug Discovery Support:

• Structure Based Drug Design (SBDD)

Functional Services:

• Gene to Structure, Protein to

Structure

• Ligand-bound structures

• Sructure refinement and annotation

• Crystal image annotation

• Low Endotoxin Proteins for

Therapeutics

• Cell Line Generation

Reagents and Cell Line Generation:• Kinases, Carboxylases, Ion channels,

GPCRs, Decarboxylases, Hydrolases, Transcription factors, NHRs, lipases, Synthetases, Reporter gene constructs, CYPs, etc.

Targets for Crystal Structures:• Kinases, Phosphatases, Proteases,

Carboxylases, NHRs, Hydrolases, Decarboxylases, Apoptotic proteins, Transferases, ß-lactamases, Deaminases, Fab, Fab-antigen complexes, epigenetic targets, Interleukins etc.

Cloning• Cloning into various vectors• Codon optimized or non-

codon optimized synthetic genes

• Full length, catalytic domain, chimeras, mutants, etc.

Protein Expression• E. coli system: Various strains,

co-expression• Insect cell system: Sf9, Sf21, Hi5• Mammalian expression system• Co-expression, dual vectors• BIIC system in place

Protein Purification• Various affinity tags: His6,

GST, HA, MBP, FLAG, etc.• Conventional techniques• Refolding from IBs• Purification using AKTAs

Crystallization• Various screening kits• Various seeding techniques• Soaking /co-crystallization

with compounds• Protein-protein complexes

Crystal Image Annotation• Manual annotation of

crystallization images with broad classifications

• Over 40 million images annotated in the past 7 years

• Customized annotation tools• 99.5% scoring accuracy• 24 hour turn-around time

to support clients based in Europe and USA

Data Collection• X-ray diffraction data

collection in house• Resolution range 1.6 - 2.9Å• Molecular weight

10kD - 90kD• ASU containing 1 - 6

molecules

Structure Determination• 20+ different target proteins

in 3+ years• Both known and novel

structures• Capabilities in experimental

phasing (SAD, MAD, etc.)

Ligand Fitting• >150 ligand bound

structures delivered for various target proteins

• Accuracy in ligand fitting using automated software

• Quick evaluation of positives in fragment-based screening

• Mode of binding evaluation to support QSAR/scaffold search

Structure Refinement• Protein-ligand structure

refinement in SBDD projects• Structure solution using MR

for known or similar targets• Structures thoroughly

validated for quality• Fast turnaround time• 4000+ structures on 100+

different target proteins refined in 5+ years

Services

Discovery EnablersStructural Biology

New Initiatives

Antibody Therapeutics

Fragment Based Drug Designing

Gram Quantity

Production from

Mammalian System


Discovery EnablersPharma IT Services

Jubilant Biosys has a strong IT services division, which is an integral part of the overall service offering of the company.

The IT team comprises of highly skilled professionals from reputed academic institutions and IT companies.

Our IT consultants have vast experience in Life Sciences with emphasis on Discovery R &D, Clinical Research, Manufacturing and Bioinformatics.

The team has expertise in developing various life science products using both Sun and Microsoft’s cutting edge technologies.

We offer following services in various phases of drug discovery:

• Product Engineering Services

• Application Development & Maintenance Services

• Solutions and Discovery Platform Development

Discovery R&D&

Bioinformatics

Life Science

ClinicalResearch

Manufacturing

• Lab Automation• Decision Support System• Research Tools and Applications• Biomarker Research Products• Public Domain Database Integration

• Enterprise Life Science Grid

Development

• Screening Platforms

• Chemistry Solutions

• Workflow Automation for Chemistry,

Structure Biology, HTS, Biology.

• Trial Stat. Orbit - EDC Component of Clinical Suite

• Clinical Knowledge Management Portal

• On-demand SaaS/Cloud data management system

• Data warehouses and Business Intelligence

• Supply Chain Management System

• Laboratory Information

Management System (LIMS)

• Chemical Inventory Management

System

• Analytical Management System

Jubilant Pharmaceutical Expertise


Biomarker Knowledge Base (BMKB):

• BMKB provides a platform through which clinical study

centers, biomarker screening sites, biobanks and statisticians

can upload, query and export data. The solution is built on

business intelligence tool and can be used in multi therapy

clinical studies.

Screening Solution:

• Developed and customized a next generation assay screening

tool for mid western pharma company.

Sample Tracking LIMS:

• Customizable solution for user definable business process to

manage the sample process workflow system from various

locations spread globally having efficient accession system to

capture sample, gene, patient and services information.

PathArt:

• It is a pathway articulator tool with rich user interface built

on manually curated pathway information & public domain

databases.

Compound Registration System:

• In-house solution to register the compounds with structure

with structure search ability linked with supply chain

management system and analytical reporting system.

Jubilant Advantage

- Experienced IT team with application development

experience in compound management, assay data handling

software

- State-Of-the- Art in-house life sciences testing environment

- One stop shop for end-to-end Healthcare & Life Science

solutions

- Expertise in informatics (Bio & Chemo informatics) -

commercial product development on pathways, biomarkers &

pharmacology (lead identification and optimization)

- Hand-on experience in integration of 3rd party analytical tools

like genespring, spotfire, pathAssist with custom solutions

- Well versed with JChem SDK, ISIS Host/Base, Kectcher, Bingo,

Indigo, JSDraw for chemistry solutions

- Custom workflow automation solutions for Informatics,

Computational Chemistry, Structure Biology, HTS, Biology, In-vivo

Some specific Product Engineering examples are:

GenomicsTarget

IdentificationTarget

Validation

Chemistry

HT Screening

Clinical Development

Development Candidates

Lead Optimization

Chemical Hits

Genomics Tool Development

Informatics Database Design

CDMS Development

CTMS Development

Biology LIMS Development

System Biology Model Development

Biology LIMS Development

Small Molecules Data Analysis

Microarray Data Analysis

Pathway Data Analysis Comparative

Gene AnalysisAssay Data

Analysis

Compound Registration & Management

Pharmacophore Modeling

ELN Design

Assay Data Validation

Homology Modeling

Chemical Tracking &Inventory Management

2D / 3D QSAR Modeling

Chemical Libraries Database

Discovery EnablersPharma IT Services


Jubilant offers Informatics services, products, customized knowledge platforms, off-the shelf databases and tailor-made Target Knowledge Packages / reports to accelerate Drug Discovery and Development.

AREAS OF EXPERTISE:

Domain expertise in areas as Oncology, CNS, Metabolic Disorders Asthma/COPD, CVD data integration from public domain and custom data bases, building standards and Ontologies, building and interfacing applications for query and analysis.

Tools : Scientific literature, Patents, open domain data sources

Databases : Public domain databases, Jubilant Proprietary databases

Analytics : Software development, 3rd party tool integration, predictive analytics

Team : A highly skilled team of 60+ scientists with extensive scientific domain expertise

• To Identify new Targets and validate targets

• To identify biomolecules in regulatory pathways

• To offer decision support for molecular design

• To explore new indications for existing targets to help in drug repositioning

Pathway Analysis

Biomarker

Target Knowledge Packages

Informatics Enablers for Discovery

Customized Discovery Informatics & Curation Services

Target Selection and Validation

Hit and Lead Identification

Clinical and Health care informatics

Lead Optimization (Pre-Clinical Candidate)

• Genomics tools development• Microarray data analysis• Pathway visualization

tools• Biomarker analysis tools• Homology modeling

tools• Structure search tools

• Assay data analysis• Assay data validation• Compound

Management• Chemical tracking and

Inventory control• Discovery databases• Database Analytics• PK/PD Analytics

• 2D /3D QSAR Modeling tool

• Pharmacophore Modeling

• PK/PD Analytical Tools• Homology Modeling• Structure Refinement,

Annotation • PK / PD correlation

• CTMS Development• EDC & CDMS systems• Biobank Management• Samples management

and tracking• Biomarkers• Tissue Annotation• PV Support and

Analytics

Tech

nolo

gy a

nd

Tool

s Sol

ution

s

• Pathway data curation and analysis• Biomarker knowledge & discovery• Target Knowledge Package• Microarray data analysis• Genomics data analytics• Biology - Drug databases

• Small Molecule databases curation - Kinase, GPCR, Ion Channel, Protease, NHR, Phosphodiesterase, PPIs

• Drug databases• Chemo-Informatics• PK/PD Data Analysis

• Clinical trial intelligence bank

• Adverse events data, Pharmacokinetics

data.• Post Marketing Data

EDC, CDMData

Cur

ation

Ser

vice

Integrated Informatics and Technology Capabilities & Solutions

Drug Discovery and Development Informatics


Drug Discovery and Development Informatics

NGS data analysis

• Microarray data analysis

• Chip-seq analysis

• Primer design

• Proteomic analysis

Database Products:

• PathArt™ - A Pathway Knowledge base and articulator

• Molsign® - A Biomarker knowledge base and report generator

• ChemBioBase™ - A small molecule database with structure based query engine

Chemistry Biology Clinical Specific Strategy

• Ligands• Assays and specificities• Chemotypes Analysis• SAR landscape• Computational

Opportunities• IP Space Analysis

• Gene and Protein Information

• Expression Information• Population & Disease• Gene Family

Relationships• Reagents• Therapeutic Areas• Pathways & Markers• Transgenic Models• Direct and Indirect

protein interactions Etc.

• Drug specific data• Inhibitor details• KOL• Investigator knowledge• Investigator Site

Knowledge

• Unique Selling Point• Competitive

Intelligence• Druggability

• Key Opinion Leader assessment

• Formularies and payer intelligence

• Clinical biomarkers

• Identifying diagnostic, efficacy, predictive disease-specific

biomarkers

• Pharmcovigilance

Clinical Informatics

Clinical trial intelligence• Scientific, clinical and health economic intelligence• Outputs presented in choice of formats• Services range from discovery to post-launch• Adverse events information• Current awareness• Clinical trial benchmarking

Drug repositioning strategy intelligence• Information on potential drug combinations• Target knowledge gathering• Identification and gathering information of drugs failed

to show efficacy in late stage clinical trials, without safety issues

• Identification of drugs stalled in development for commercial reasons

• Identification of drugs passed the point of patent expiry; or are being explored in new geographical markets

Pathway Analysis• Identification of poteintial drug targets associated with

disease• Explore regulatory mechanisms• To study Protein protein interactions, and small molecule

kinetics• Applications in systems biology, toxicogenomics, and

biomarker studies• Annotation of genes and proteins along with gene

expression profiles

Biomarkers• Data from Expression studies

• Identifying and categorizing potential biomarkers

• Clinical biomarkers

• Information for mutation, polymorphism, chromosomal

aberrations, epigenetic changes, post translational modifications

Clinical Biomarker Database

Gene Annotation Support

• Background• correction• Qspline• Quantile• Variance-Stabilizingtransformation

• Entrez Gene• Swiss prot• unigene id• Cytoband• RefSeq id

• PathART• Molsign• Disease focus

• K Means• Hierarchical• PCA

• Cut-off by M values• T-statistics• Adjust ed p-values

Annotation InterpretationDifferentialgenesNormalization Clustering

Bioinformatics


Jubilant Drug Discovery Services

• Company Founded in 2000; part of Jubilant Life Sciences

• Employees 700+ employees. Most PhDs have >10 years of US/EU Pharma experience

• Customers Global Top 10, mid-size and virtual pharmaceutical and biotech companies

Global Footprint

Noida, India

Bangalore, India

Malvern, Pennsylvania, USA

Jubilant Biosys Ltd. (Bangalore)#96, Industrial Suburb,2nd Stage, Yeshwantpur,Bangalore - 560 022, India.Tel: +91 80 66628400Fax: +91 80 66628333

Jubilant Chemsys Ltd. (Noida)Jubilant Chemsys LimitedB-34. Sector-58Noida – 201301, UP, India.Tel: +91 120 4093300Fax: +91 120 2586776

Jubilant Discovery Services (US)365, Phoenixville Pike,Malvem, PA - 19355, USATel: 610-240-6690 x101Fax: 610-240-8693

[email protected] | www.jubilantbiosys.com | [email protected] | www.jchemsys.com

affordable innovation - jubilant life sciences ltd · 2013-05-06 · molecular design...

Documents